Mobble
World · China · published 2026-08-27 · via South China Morning Post

Chinese biotech's cancer drug shows survival edge over AstraZeneca's in late-stage trial

Chinese biopharmaceutical firm Akeso said its immunotherapy drug ivonescimab extended survival compared with AstraZeneca's Imfinzi in a phase 3 trial for advanced biliary tract cancer. The study enrolled 682 patients and is the first positive phase 3 result for the drug in gastrointestinal tumours. Akeso has not yet released specific survival data, which it plans to present at an upcoming conference.

Read the full article at South China Morning Post →
Related stories
US regulator clears once-daily pill for late-stage pancreatic cancer · Latin America
Personalized mRNA therapy shows promise against melanoma in late-stage trial · Europe
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial.” Browse more stories.